2024년에 786억 달러로 추정되는 저분자 CDMO 세계 시장은 2024년부터 2030년까지 CAGR 5.8%로 성장하여 2030년에는 1,102억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 원료의약품은 CAGR 4.7%를 기록하며 분석 기간 종료시에는 698억 달러에 달할 것으로 예상됩니다. 완제의약품 부문의 성장률은 분석 기간 동안 CAGR 7.9%로 추정됩니다.
미국 시장은 206억 달러로 추정, 중국은 CAGR 5.8%로 성장 예측
미국의 저분자 CDMO 시장은 2024년에 206억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 178억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 5.8%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 5.3%와 5.0%로 예측됩니다. 유럽에서는 독일이 CAGR 4.8%로 성장할 것으로 예측됩니다.
세계 저분자 CDMO 시장 - 주요 동향 및 촉진요인 정리
저분자 CDMO가 주목받는 이유는 무엇일까? 의약품 개발 및 제조에서 CDMO의 역할에 대해 알아봅니다.
의약품 개발의 복잡성과 전문화된 개발 및 제조 수탁기관(CDMO)에 대한 수요가 증가함에 따라 저분자 CDMO는 제약 산업에서 중요한 역할을 하고 있습니다. 기존 의약품 제제의 골격을 이루는 저분자는 광범위한 치료 용도, 비용 효율성, 확립된 규제 경로로 인해 의약품 시장을 계속 독점하고 있습니다. 제약기업들이 제조 및 개발 프로세스를 전문 CDMO에 아웃소싱하는 방향으로 전환하면서 시장이 크게 확대되고 있습니다. 신속한 의약품 개발, 비용 최적화, 유연한 제조 능력에 대한 수요가 증가함에 따라 저분자 CDMO의 필요성이 더욱 커지고 있습니다. 대기업부터 신생 바이오테크놀러지 기업까지, 바이오제약 기업들은 규제 준수와 제조 확장성을 보장하면서 시장 출시 시간을 단축하기 위해 CDMO에 의존하고 있습니다. 제약 업계의 상황이 발전함에 따라 저분자 CDMO는 신약개발과 상업적 생산의 격차를 해소하는 역할을 할 것으로 기대됩니다.
기술 발전이 저분자 CDMO의 혁신을 어떻게 촉진하고 있는가? 원료의약품 제조 및 공정 최적화의 진보를 살펴봅니다.
합성 화학, 공정 최적화 및 자동화 분야의 기술 혁신은 저분자 CDMO의 효율성을 크게 향상시켰습니다. 연속 제조 기술은 게임 체인저로 등장하여 실시간 모니터링, 수율 효율 향상, 폐기물 감소를 가능하게 했습니다. 하이스루풋 스크리닝과 AI를 통한 의약품 합성 모델링을 포함한 첨단 분석 기술은 화합물 선택과 공정 개발을 간소화했습니다. 또한, 친환경 용매와 효소 촉매 기술을 사용하여 환경에 미치는 영향을 최소화하고 세계 지속가능성 목표에 부합하는 그린 케미스트리의 원칙을 통합하여 환경 친화적인 용매와 효소 촉매 기술을 채택하고 있습니다. 모듈식 생산 설비와 일회용 바이오리액터를 사용하여 운영의 유연성을 더욱 향상시킴으로써 CDMO는 변화하는 시장 수요에 신속하게 대응할 수 있게 되었습니다. R&D 및 디지털화에 대한 투자가 증가함에 따라 저분자 CDMO는 혁신, 자동화 및 확장 가능한 제조 솔루션을 통해 의약품 개발 파이프라인을 강화할 준비가 되어 있습니다.
저분자 CDMO 시장의 성장을 저해하는 요인은? 규제, 공급망, 비용 압력에 대한 대응
저분자 CDMO에 대한 수요가 증가하고 있음에도 불구하고, 엄격한 규제 준수, 공급망 제약, 비용 압박 등 몇 가지 과제가 남아있습니다. 제약 산업은 규제가 엄격하고 미국 FDA, 유럽의약품청(EMA) 등의 가이드라인이 진화함에 따라 새로운 품질 및 안전 기준에 대한 지속적인 적응이 요구되고 있습니다. 전 세계적으로 규제 승인의 복잡성으로 인해 의약품 개발 일정이 지연되고 CDMO와 고객사 모두 비용 부담이 증가합니다. 세계 위기와 원료 부족으로 인한 공급망 혼란은 원료의약품(API) 조달과 생산능력에 영향을 미치고 있습니다. 또한, CDMO 간의 치열한 경쟁은 가격 압박으로 이어져 주요 기업들은 고품질 서비스를 제공하면서도 업무 효율성을 유지해야 하는 과제를 안고 있습니다. 이러한 과제를 해결하기 위해서는 규제 준수 프레임워크, 다양한 공급망, 비용 효율적인 생산 방식에 대한 전략적 투자가 필요하며, 조사 방법론의 지속적인 성장이 요구됩니다.
저분자 CDMO 시장의 성장을 촉진하는 요인은 무엇인가? 주요 성장 요인 및 산업 동향 파악
저분자 CDMO 시장의 성장은 의약품 제조 아웃소싱 수요 증가, 합성 화학의 발전, 특수 치료제의 부상 등 여러 가지 요인에 의해 이루어지고 있습니다. 위탁 기반 의약품 개발이 선호되면서 제약사는 전문 CDMO와 제휴하게 되었고, 사내 인프라의 필요성이 줄어들어 의약품의 상업화가 가속화되고 있습니다. 정밀의료와 표적 저분자 치료의 확대로 틈새 의약품 개발에 특화된 CDMO의 사업 기회가 더욱 확대되고 있습니다. 또한, 신흥 시장의 부상과 아시아태평양 및 라틴아메리카의 의약품 투자 증가는 CDMO의 세계 진출을 위한 새로운 성장의 길을 열어주고 있습니다. 제약 산업이 기술 발전과 규제 변화에 따라 계속 진화하고 있는 가운데, 저분자 CDMO는 앞으로도 의약품 개발의 핵심이 될 것이며, 전 세계적으로 기술 혁신과 대규모 생산을 지원할 것으로 예상됩니다.
Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.
Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
KSM
영문 목차
영문목차
Global Small Molecule CDMO Market to Reach US$110.2 Billion by 2030
The global market for Small Molecule CDMO estimated at US$78.6 Billion in the year 2024, is expected to reach US$110.2 Billion by 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Active Pharmaceutical Ingredients, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$69.8 Billion by the end of the analysis period. Growth in the Finished Drug Products segment is estimated at 7.9% CAGR over the analysis period.
The U.S. Market is Estimated at US$20.6 Billion While China is Forecast to Grow at 5.8% CAGR
The Small Molecule CDMO market in the U.S. is estimated at US$20.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$17.8 Billion by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.3% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.
Global Small Molecule CDMO Market - Key Trends & Drivers Summarized
Why Are Small Molecule CDMOs Gaining Traction? Examining Their Role in Pharmaceutical Drug Development and Manufacturing
The increasing complexity of drug development and the rising demand for specialized contract development and manufacturing organizations (CDMOs) have positioned small molecule CDMOs as vital players in the pharmaceutical industry. Small molecules, which form the backbone of traditional drug formulations, continue to dominate the pharmaceutical market due to their broad therapeutic applications, cost-effectiveness, and well-established regulatory pathways. With pharmaceutical companies shifting focus toward outsourcing manufacturing and development processes to specialized CDMOs, the market has seen significant expansion. The rising demand for rapid drug development, cost optimization, and flexible manufacturing capabilities has further fueled the need for small molecule CDMOs. Biopharmaceutical companies, ranging from large-scale enterprises to emerging biotech firms, rely on these CDMOs to accelerate time-to-market while ensuring regulatory compliance and production scalability. As the pharmaceutical landscape evolves, small molecule CDMOs are expected to play an even greater role in bridging the gap between drug discovery and commercial production.
How Are Technological Advancements Driving Innovation in Small Molecule CDMOs? Exploring Advancements in API Manufacturing and Process Optimization
Technological innovations in synthetic chemistry, process optimization, and automation have significantly enhanced the efficiency of small molecule CDMOs. Continuous manufacturing technologies have emerged as a game-changer, allowing for real-time monitoring, improved yield efficiency, and reduced waste. Advanced analytical techniques, including high-throughput screening and AI-driven drug synthesis modeling, have streamlined compound selection and process development. Additionally, the integration of green chemistry principles has led to the adoption of eco-friendly solvents and enzymatic catalysis techniques, minimizing environmental impact and aligning with global sustainability goals. The use of modular production facilities and single-use bioreactors has further improved operational flexibility, enabling CDMOs to quickly adapt to changing market demands. With increasing investments in R&D and digitalization, small molecule CDMOs are poised to enhance drug development pipelines through innovation, automation, and scalable manufacturing solutions.
What Challenges Are Hindering the Growth of the Small Molecule CDMO Market? Addressing Regulatory, Supply Chain, and Cost Pressures
Despite the growing demand for small molecule CDMOs, several challenges persist, including stringent regulatory compliance, supply chain constraints, and cost pressures. The pharmaceutical industry is heavily regulated, with evolving guidelines from agencies such as the U.S. FDA and EMA requiring continuous adaptation to new quality and safety standards. The complexity of global regulatory approvals can delay drug development timelines, adding to the cost burden for both CDMOs and their clients. Supply chain disruptions, exacerbated by global crises and raw material shortages, have impacted active pharmaceutical ingredient (API) sourcing and production capabilities. Additionally, intense competition among CDMOs has led to price pressures, requiring companies to maintain operational efficiency while delivering high-quality services. Addressing these challenges requires strategic investments in regulatory compliance frameworks, diversified supply chains, and cost-effective production methodologies to ensure sustainable growth in the small molecule CDMO sector.
What’s Driving the Growth of the Small Molecule CDMO Market? Identifying Key Expansion Factors and Industry Trends
The growth in the small molecule CDMO market is driven by several factors, including increasing demand for outsourced pharmaceutical manufacturing, advancements in synthetic chemistry, and the rise of specialty therapeutics. The growing preference for contract-based drug development has encouraged pharmaceutical firms to partner with specialized CDMOs, reducing the need for in-house infrastructure and accelerating drug commercialization. The expansion of precision medicine and targeted small-molecule therapies has further created opportunities for CDMOs specializing in niche drug development. Additionally, the rise of emerging markets and increased pharmaceutical investments in Asia-Pacific and Latin America have opened new growth avenues for CDMOs seeking global expansion. As the pharmaceutical industry continues to evolve with technological advancements and regulatory changes, small molecule CDMOs are expected to remain a cornerstone of drug development, supporting innovation and large-scale production worldwide.
SCOPE OF STUDY:
The report analyzes the Small Molecule CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Product (Active Pharmaceutical Ingredients, Finished Drug Products); Drug Type (Innovators, Generics); Application (Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation, Others)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 42 Featured) -
Aenova Group
AGC Biologics
Alcami Corporation
Apeloa Pharmaceutical
Aurigene Pharmaceutical Services
Boehringer Ingelheim
Cambrex Corporation
Catalent, Inc.
CordenPharma International
CoreRx, Inc.
Delpharm
Emergent BioSolutions
Eurofins Scientific
Fujifilm Diosynth Biotechnologies
Hovione
Labcorp Drug Development
Lonza Group
MilliporeSigma
Patheon (Thermo Fisher Scientific)
PCI Pharma Services
Piramal Pharma Solutions
Recipharm AB
Samsung Biologics
Siegfried Holding AG
Teva Pharmaceutical Industries
Thermo Fisher Scientific
Veranova
Wheeler Bio
WuXi AppTec
Zhejiang Huahai Pharmaceutical
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Small Molecule CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Outsourcing by Pharma and Biotech Innovators Throws the Spotlight on Small Molecule CDMO Partnerships
Growth in Complex Chemistry and High-Potency API Development Drives Specialized CDMO Capabilities
OEM Expansion Into Early-Stage and End-to-End CDMO Models Strengthens Client Lifecycle Integration
Surging Pipeline of Orphan Drugs, Oncology Therapeutics, and CNS Agents Spurs API Volume Growth
OEM Emphasis on Continuous Manufacturing, Microreactors, and Flow Chemistry Enhances Process Efficiency
Increasing Demand for Regulatory Compliant Facilities Drives Investment in GMP Infrastructure Expansion
OEM Investment in HPAPI and Controlled Substance Manufacturing Strengthens Differentiation
Growth in Accelerated Approval Pathways and 505(b)(2) Strategies Spurs Flexible Manufacturing Needs
OEM Collaboration With Innovators for Route Scouting and Synthetic Optimization Enhances Drug Viability
Rising Complexity of Multi-Step Synthesis and Chiral Catalysis Drives Strategic CDMO Engagement
OEM Focus on Real-Time Analytics, PAT Integration, and QbD Enhances Quality Assurance
Expansion of Bioavailability Enhancement Technologies Supports Value-Added CDMO Services
OEM Acquisition of CRO Capabilities Enables Seamless Transition From Preclinical to Commercial Scale
Increasing Regulatory Oversight in Emerging Markets Spurs Demand for US/EU Inspected CDMO Facilities
OEM Strategies for Geographical Diversification Mitigate Supply Chain and Geopolitical Disruptions
Growth in Demand for Specialized Dosage Forms Such as ODT, SR, and Nanoformulations Spurs Innovation
OEM Development of High-Capacity Spray Drying and Crystallization Facilities Enhances Solubility Projects
Rising Focus on Cost-Effective Late-Phase Scale-Up Solutions Drives Competitive Differentiation
OEM Integration of Digital Supply Chain, Forecasting Tools, and Batch Traceability Enhances Partner Collaboration
Focus on Environmental Compliance, Solvent Recovery, and Waste Reduction Reinforces ESG Credentials of CDMOs
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Small Molecule CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Small Molecule CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Small Molecule CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Small Molecule CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Active Pharmaceutical Ingredients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Active Pharmaceutical Ingredients by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Active Pharmaceutical Ingredients by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Finished Drug Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Finished Drug Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Finished Drug Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Innovators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Innovators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Innovators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Generics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Central Nervous System Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Central Nervous System Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Central Nervous System Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Autoimmune / Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Autoimmune / Inflammation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Autoimmune / Inflammation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 32: USA Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: USA Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: USA 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
TABLE 35: USA Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: USA Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: USA 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
TABLE 38: USA Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: USA Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: USA 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
CANADA
TABLE 41: Canada Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Canada Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: Canada 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
TABLE 44: Canada Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Canada Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: Canada 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
TABLE 47: Canada Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: Canada 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
JAPAN
Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 50: Japan Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Japan Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Japan 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
TABLE 53: Japan Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Japan Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Japan 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
TABLE 56: Japan Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Japan 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
CHINA
Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 59: China Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: China Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: China 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
TABLE 62: China Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: China Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: China 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
TABLE 65: China Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: China Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: China 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
EUROPE
Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 68: Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 69: Europe Historic Review for Small Molecule CDMO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Europe 15-Year Perspective for Small Molecule CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 71: Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Europe Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Europe 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: Europe 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: Europe 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
FRANCE
Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 80: France Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: France Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: France 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
TABLE 83: France Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: France Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: France 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
TABLE 86: France Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: France Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: France 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
GERMANY
Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 89: Germany Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Germany Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Germany 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
TABLE 92: Germany Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Germany Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Germany 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
TABLE 95: Germany Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Germany 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
ITALY
TABLE 98: Italy Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Italy Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Italy 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
TABLE 101: Italy Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Italy Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: Italy 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
TABLE 104: Italy Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: Italy 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
UNITED KINGDOM
Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 107: UK Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: UK Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: UK 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
TABLE 110: UK Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: UK Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: UK 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
TABLE 113: UK Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: UK Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: UK 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Rest of Europe Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: Rest of Europe 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: Rest of Europe Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: Rest of Europe 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Rest of Europe Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: Rest of Europe 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Small Molecule CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Asia-Pacific Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: Asia-Pacific 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Asia-Pacific Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: Asia-Pacific 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Asia-Pacific Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Asia-Pacific 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
REST OF WORLD
TABLE 134: Rest of World Recent Past, Current & Future Analysis for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Rest of World Historic Review for Small Molecule CDMO by Product - Active Pharmaceutical Ingredients and Finished Drug Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Rest of World 15-Year Perspective for Small Molecule CDMO by Product - Percentage Breakdown of Value Sales for Active Pharmaceutical Ingredients and Finished Drug Products for the Years 2015, 2025 & 2030
TABLE 137: Rest of World Recent Past, Current & Future Analysis for Small Molecule CDMO by Drug Type - Innovators and Generics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: Rest of World Historic Review for Small Molecule CDMO by Drug Type - Innovators and Generics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: Rest of World 15-Year Perspective for Small Molecule CDMO by Drug Type - Percentage Breakdown of Value Sales for Innovators and Generics for the Years 2015, 2025 & 2030
TABLE 140: Rest of World Recent Past, Current & Future Analysis for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: Rest of World Historic Review for Small Molecule CDMO by Application - Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: Rest of World 15-Year Perspective for Small Molecule CDMO by Application - Percentage Breakdown of Value Sales for Oncology, Cardiovascular Disease, Central Nervous System Conditions, Autoimmune / Inflammation and Others for the Years 2015, 2025 & 2030
